- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
- Anaptys Announces Participation in November Investor Conferences
- Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
- Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
- Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
More ▼
Key statistics
On Friday, AnaptysBio Inc (AN6:FRA) closed at 19.50, -20.73% below its 52-week high of 24.60, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.40 |
---|---|
High | 19.50 |
Low | 17.40 |
Bid | 19.50 |
Offer | 19.70 |
Previous close | 17.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 27.32m |
Free float | 26.66m |
P/E (TTM) | -- |
Market cap | 515.50m USD |
EPS (TTM) | -6.07 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:55 BST.
More ▼